title: Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelin.
abstract: We tested the effect of dose of GnRH superagonist on pituitary and testicular function in a study with four groups of four male dogs. The Controls received blank implants and the other three groups received implants containing 3, 6 or 12 mg deslorelin (D-Trp6-Pro9-des-Gly10-GnRH ethylamide). In all deslorelin-treated groups, there was initially an acute increase in plasma concentrations of LH and testosterone, followed by declines such that both hormones became undetectable after approximately 12 days. There was a dose-response in some of these early aspects of the hormone profiles. With respect to long-term effects of treatment, the 12-mg dose had significantly greater effects than the smaller doses for the duration of minimum testicular volume [366 +/- 77, mean +/- SEM (3 mg), 472 +/- 74 (6 mg), and 634 +/- 59 (12 mg) days], absence of ejaculate [416 +/- 88 (3 mg), 476 +/- 83 (6 mg), and 644 +/- 67 (12 mg) days], undetectable plasma concentrations of LH and testosterone [367 +/- 64 (3 mg), 419 +/- 72 (6 mg), and 607 +/- 69 (12 mg) days], the delay until complete recovery of LH and testosterone secretion [394 +/- 65 (3 mg), 484 +/- 72 (6 mg) and 668 +/- 47 (12 mg) days], and the delay until testes had regrown to normal volume [408 +/- 77 (3 mg), 514 +/- 74 (6 mg), 676 +/- 59 (12 mg) days]. The time taken to restore full ejaculates was also longest for the 12-mg dose: 716 +/- 67 (12 mg) days vs 440 +/- 66 (3 mg) and 538 +/- 83 (6 mg) days after implantation. There was no correlation between delay to recovery of normal ejaculate quality and body mass. We conclude that the dose-response relationship with deslorelin implants is not expressed with respect to the degree of suppression of reproduction, but on the maximum duration of suppression and thus to delay until recovery.
authors.affiliation: Division of Veterinary and Biomedical Sciences, Murdoch University, Murdoch, WA, Australia. arjunavet03@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: Junaidi
authors.forename: P E
authors.initials: PE
authors.lastname: Williamson
authors.forename: G B
authors.initials: GB
authors.lastname: Martin
authors.forename: M A
authors.initials: MA
authors.lastname: Blackberry
authors.forename: J M
authors.initials: JM
authors.lastname: Cummins
authors.forename: T E
authors.initials: TE
authors.lastname: Trigg
mesh_terms: D000818:Animals; D003272:Contraceptive Agents, Male / Q000008:administration & dosage; D004285:Dogs / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D007700:Kinetics; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology; D012661:Semen / Q000166:cytology / Q000187:drug effects; D013076:Sperm Count; D013081:Sperm Motility; D013737:Testis / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D003272:Contraceptive Agents, Male; D004343:Drug Implants; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; C066438:deslorelin